Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lung Neoplasms 29Ovarian Neoplasms 27Fallopian Tube Neoplasms 24Carcinoma, Non-Small-Cell Lung 23Colorectal Neoplasms 16Melanoma 12Carcinoma, Renal Cell 12Carcinoma, Hepatocellular 12Squamous Cell Carcinoma of Head and Neck 11Pancreatic Neoplasms 11Glioblastoma 11Breast Neoplasms 11Triple Negative Breast Neoplasms 10Urinary Bladder Neoplasms 8Prostatic Neoplasms 8Neoplasm Metastasis 8Uterine Cervical Neoplasms 7Brenner Tumor 7Mycosis Fungoides 6Colonic Neoplasms 6Brain Neoplasms 6Rectal Neoplasms 5Multiple Myeloma 5Lymphoma, T-Cell, Cutaneous 5Endometrial Neoplasms 5Sezary Syndrome 4Sarcoma 4Neoplasms 4Nasopharyngeal Carcinoma 4Lymphoma, Large B-Cell, Diffuse 4

Interventions

pembrolizumab 7Nivolumab 5durvalumab 3fludarabine 2avelumab 2atezolizumab 2Cyclophosphamide 2tremelimumab 1relatlimab 1lentiviral minigene vaccine of COVID-19 coronavirus 1fludarabine phosphate 1epacadostat 1bintrafusp alfa protein, human 1aldesleukin 1Therapeutics 1Temozolomide 1Surgical Procedures, Operative 1Specimen Handling 1Oxaliplatin 1Neoadjuvant Therapy 1Ipilimumab 1Interleukin-2 1Injections 1Immunoglobulin G 1High-Throughput Nucleotide Sequencing 1Educational Status 1Drug Therapy 1Docetaxel 1Disulfides 1Chemotherapy, Adjuvant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Microsatellite Instability × Immunoglobulin G × Clear all
NCT02966587 2018-01-17

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

University of Washington

Phase 2 Withdrawn

Microsatellite Instability

Data powered by HemOnc (CC BY 4.0) Colophon âš¡